Treatment Delay and Total Delay among Pulmonary Tuberculosis Patients in the North of Iran: Application Survival Data Analysis

Jamshid Yazdani-Charati ¹, Mohammad Sadegh Rezai ², Afsane Fendereski ³, Soraya Mohammadi ³, Nadia Alipour ³

¹ Department of Biostatistics, Health Sciences Research Center, School of Health Sciences, Mazandaran University of Medical Sciences, Sari, Iran, ² Infectious Disease Research Center with Focus on Nosocomial Infections, Mazandaran University of Medical Sciences, Sari, Iran, ³ Students Research Committee, Department of Biostatistics, School of Health, Mazandaran University of Medical Sciences, Sari, Iran.

Background: Tuberculosis (TB) remains the leading cause of death among infectious diseases worldwide. Identifying the factors associated with the treatment delay and total delay would be helpful in the prevention of tuberculosis and in reducing the burden on the health care system. The objective of this study was to assess the treatment delay and total delay in TB patients and investigate the factors causing these delays.

Materials and Methods: This was a longitudinal study conducted in 2009-2015. Our study consisted of 1694 TB patients registered in the TB center of Mazandaran province. Data regarding the patients’ demographic characteristics and clinical factors associated with treatment delay and total delay were analyzed. Kaplan Meier plots and log rank tests were used to assess the survival pattern. Cox proportional hazards model for multivariable analysis was discussed. We used mean values and median (Q2) [first quartile (Q1)-third quartile (Q3)] to describe delays.

Results: The median treatment delay and total delay were 35 (ranged 23-80) and 36 (ranged 24-82) days, respectively. The mean age of TB patients was 47.4±0.3. No significant association was found between the location of residence, nationality, gender and type of pulmonary TB patients with treatment delay and total delay. Additionally, age, prison status of patients, HIV test, and contact history had a significant relationship with the treatment delay and total delay (p-value <0.05). It was shown that the median total delay in men patients in the ≤14 year-old age group, imprisoner patients, rural patients, patients who have not received an HIV test, smear negative patients, those who are Iranian, and TB patients whose contact history was unknown was lower than that of others. The highest median treatment delay and total delay was in the >60 age groups, and were 41 and 44 days, respectively. Treatment delay was the same as the total delay except in the place of residence variable; median treatment delay among urban patients was less than that of rural patients.

Conclusion: According to this study age, prison status of patients, HIV test and contact history had a significant relationship with the treatment delay and total delay (P-value<0.05). Understanding the factors that are closely associated with these delays is essential to effectively control TB and could be helpful in reducing these delays.

Key words: Tuberculosis, Cox Regression, Survival, Treatment Delay, Total Delay
INTRODUCTION

Despite the existence of effective treatment methods, tuberculosis (TB) remains one of the major infectious diseases prevalent in most countries (1-3). Based on a WHO report, there were an estimated 10.4 million incident TB cases worldwide, of which 5.9 million (56%) were among men, 3.5 million (34%) among women and 1.0 million (10%) among children (4). The incidence rate in Iran was reported as 12.6 per 100,000 population, and this rate is the highest in Sistan-Baluchistan and Golestan provinces (5, 6).

A national survey conducted in Iran in 2003 showed that the median delay in diagnosis and treatment in patients with sputum positive pulmonary tuberculosis was 92 days (with an average of 120±10 days) and the median patient delay and median physicians delay in diagnosis was 20 (with an average of 44±6 days) and 46 days (with an average of 76±8 days), respectively (7). Transmission of TB is difficult to control, and one index case may infect a large number of secondary cases if left untreated (8-10); therefore, reducing the time delay from symptom onset initiation of treatment is required for better management of TB (9,11). The delay in treatment could be due to the delay in diagnosis by the physicians or due to the failure of the treatment provided, and due to these reasons, treatment delay may increase (12). Delay in accessing TB care is common in both industrialized and developing countries. However, there is no international consensus on what constitutes an acceptable delay (13). The average delay in low-income countries has been reported to be 9.7 weeks (14). Since delays may increase mortality, the factors affecting treatment delay are of key importance in TB management (14, 15). Since these delays may have adverse effects on the wellbeing of the society and the health system by possibly increasing the treatment duration, the aim of this study was to evaluate the survival of these patients and determine the factors that cause treatment delays in Mazandaran. Our study results would be useful for the health authorities and strategic planners in the design and implementation of interventional TB control programs, and in finding ways to treat and diagnose patients as early as possible.

MATERIALS AND METHODS

Study participants or Data collection

This was a longitudinal study conducted during 2009–2015 in Mazandaran province. The names and contact information of all patients presented to the medical centers affiliated to Mazandaran University of Medical Sciences and Babol University of Medical Sciences were extracted from the TB registry. This data extraction was performed in compliance with the rules and regulations of the ethics committees of Mazandaran University of Medical Sciences and Babol University of Medical Sciences. Patients suspected of having TB based on signs and symptoms were diagnosed using the sputum smear test and pathological examinations by the physicians of the health centers or private clinics, and were then referred to TB registry centers for medical treatment. Patients who their first symptom date or diagnosis date or treatment dates were unknown considered as censored data. All the data regarding 1694 TB patients who had various forms of TB were collected from 18 areas in Mazandaran province during the 6-year period. Demographic characteristics, such as age, gender, type of disease, HIV testing (whether patient has been tested for HIV or not), nationality, prison status (patients who were in prison or not), contact history, date of diagnosis, date of first symptom(s), date of treatment, and residential location were evaluated.

Data analysis

We assessed the demographic characteristics affecting the treatment delay and total delay in patients, using Cox semi-parametric regression analysis to determine the relationship with the probability of survival in all subgroups of the population relative to baseline category (BL), and to determine the hazard ratio. T being the treatment delay or total delay (days), the value of T can reflect a probability distribution. The main form of this model consists of:
\[ \ln(h(T)) = \ln(h_0(T)) + \sum_{i=1}^{p} x_i \beta_i \]

In this model, \( x_1, x_2, \ldots, x_p \) are covariates, \( \beta_1, \beta_2, \ldots, \beta_p \) are estimated regression coefficients, and \( h_0(T) \) is the baseline hazard rate when all covariates are equal to zero (16). First, we used the Kaplan-Meier plot for treatment delay (time between diagnosis and the treatment date) and total delay (time between the first symptom(s) and the treatment time); then we compared this using log-rank test. Log rank (Mantel-Cox) test for the equality of survival distributions was used to analyze the significance of survival difference among the categorical variables. For single variable analysis p<0.4 was considered significant.

We then performed Cox proportional hazards regression analysis to evaluate the impact of age, gender, nationality, place of residence, prison status (patients who were in prison or not), date of diagnosis, date of the first symptom, date of treatment, contact history with TB patient (we defined dummy variable for contact history), Type of pulmonary TB (Smear positive, Smear negative), HIV test status, treatment delay. We used mean and quartiles median (Q2) [first quartile (Q1) - third quartile (Q3)] to describe delays. Statistical analyses were performed using SPSS Ver. 16 software; and the value of α=0.05 was considered significant.

**RESULTS**

Of the 1694 registered TB patients selected for analysis, 1120 (48.2%) were male patients and 574 (24.7%) were female patients. Additional information is shown in Table 1. The mean age of male and female TB patients was 45.97±19.71 and 50.19±22.35 years, respectively. The mean age of all patients was 47.40±20.3. The median (Q1- Q3) treatment delay and total delay were 35 (23 - 80) and 36 (24-82) days, respectively. Moreover, the mean treatment delay and total delay were 68.29 and 69.9 days, respectively. Table 2 illustrates the Cox regression analysis. First, variables with p-values less than 0.4 in log rank test were entered in the Cox regression model. After distinguishing those variables, we used the semi-parametric Cox and determined the variables affecting the treatment delay and total delay.

Table 2 shows that the variables of age, prison status of patients, HIV test, and patients who their contact history were unknown had significant relationship with treatment delay and total delay (p-value<0.05). As the p-value for age was less than 0.05, there were differences in total delay and treatment delay for age variable. With respect to hazard ratio for age variable, we noted that each 1-year increase in age resulted in almost 99.6 % decrease in both delays.

A significant difference was observed between total delay and treatment delay for patients who their contact history were unknown (p-values<0.001). The longest mean (median) estimated times for total delay was 85.53 (56) days and 83.39 (54) days for treatment delay. The risk of increase in treatment delay and total delay for patients who their contact history’s status with another TB patient were unknown was 67.5% and 66.8% less than patients whose had not contact history (baseline category), respectively.

As the p-value was <0.001 for both delays with respect to prison status, we concluded that there was significant evidence for the difference in survival times. The longest mean (median) estimated time for total delay was 72.87(41) days, for patients that were not in prison and the shortest total delay was 46.72(30) days, for prisoner patients. Hazard ratios were 1.351 and 0.722 for treatment delay and total delay, respectively. Therefore, treatment delay for patients who are not in prison was 35.1 times more than that of prisoner patients and total delay for patients who are not in prison was 72.2 percent less than that of prisoner patients.

Since the p-value variable for both delays was less than 0.05 with respect to the HIV testing, we concluded that there was significant evidence for a difference in survival times for patients who received HIV test regardless of the test result. It was noted that both delays were 28.7 % times greater in patients who did not receive an HIV test as compared to those who received an HIV test.
The estimated median (mean) values for the treatment delay was 33 (66.65) days for male patients and 38 (71.47) days for female patients. In addition, the estimated median (mean) of total delay was 35 (68.25) days for male patients and 40 (73.16) days for female patients. There were no differences in total delay and treatment delay for male patients and female patients (Figures 1 and 2). The median (mean) time between the first symptom(s) date and treatment date (total delay) was 36 (69.60) and 55 (82.68) for Iranians and Afghans, respectively. However, there were no differences in total delay and treatment delay between Iranians and Afghans. Although there were no differences between smear positive patients and smear negative patients, both treatment delay and total delay for the smear positive patients were greater than that of the smear negative patients.

### Table 1. Characteristics of study participants (N=1694) in Mazandaran, Iran, 2009-2015

| Characteristic | N(percent) | Treatment delay | Total delay |
|---------------|------------|-----------------|-------------|
|               |            | Mean Median     | Quartiles 1st | Mean Median 1st 3rd |
| **Gender**    |            |                |             |                  |
| Female        | 574(33.88) | 71.47 38 23 80 | 73.16 40 24 82 |
| Male          | 1120(66.12)| 66.65 33 22 79.25 | 68.26 35 24 82 |
| **Age group** |            |                |             |                  |
| <14           | 17(0.7)    | 39.64 28 11.5 38 | 40.35 28 11.5 38.5 |
| 15-24         | 172(7.4)   | 50.23 31 20 64.5 | 51.65 31 23 66.25 |
| 25-39         | 558(24)    | 63.33 33 23 74 | 64.30 36 24 74.5 |
| 40-60         | 439(18.9)  | 71.89 34 20 87.25 | 74.71 36 22 90 |
| >60           | 508(21.8)  | 77.61 41 24 90 | 79.05 44 26 90 |
| **Prison status** |        |                |             |                  |
| Yes           | 192(8.3)   | 45.06 30 18 31 | 46.72 30 19 33 |
| No            | 1502(64.6) | 71.24 38 23 84.25 | 72.87 41 25 88 |
| **Residence** |            |                |             |                  |
| Rural         | 687(40.5)  | 67.33 35 24 78.5 | 68.83 36 25 80 |
| Urban         | 1007(59.45)| 68.93 34 22 80 | 70.65 37 23 82 |
| **HIV test status** |          |                |             |                  |
| Known         | 301(17.77) | 75.22 57 31 91 | 77.15 59 31 92 |
| Unknown       | 139(82.23) | 66.79 31 20.75 73 | 63.36 33 22 76 |
| **Type of pulmonary TB** |          |                |             |                  |
| Smear positive | 1324(56.9)| 67.96 36 25 81 | 69.7 38 27 84 |
| Smear negative | 370(15.9) | 69.4 32 15 70.25 | 70.67 33 16 72.25 |
| **Nationality** |            |                |             |                  |
| Iranian       | 1653(71.1) | 67.98 34 22.25 79.75 | 69.6 36 24 81.75 |
| Afghan        | 41(1.8)    | 80.43 53 28.5 95 | 82.68 55 30 95 |
| **Contact History** |          |                |             |                  |
| Yes           | 275(11.8)  | 70.96 42 25 92 | 72.63 45 26 92 |
| No            | 702(30.2)  | 83.39 54 30 92 | 85.53 56 30 93 |
| Unknown       | 715(30.7)  | 52.18 30 15 36 | 53.32 30 16 59 |

### Table 2. The significant variables in the Cox multi-variable for the patient’s with TB in Mazandaran province during 2009-2015

| Variable                  | Treatment Delay          | Total Delay           |
|---------------------------|--------------------------|-----------------------|
|                          | HR* (95% CI) P-value     | HR* (95% CI) P-value  |
| **Age**                  |                          |                       |
| Female (BL)               | 0.996 (0.994-0.999) 0.007| 0.997 (0.994-0.999) 0.008|
| Male                      | 0.971 (0.874-1.060) 0.592| 0.975 (0.877-1.084) 0.635|
| **Gender**                |                          |                       |
| Smear positive (BL)       | 1.105 (0.983-1.243) 0.095| 1.116 (0.992-1.255) 0.068|
| Smear negative            |                          |                       |
| Yes (BL)                  | 1.351 (1.149-1.590) <0.001| 0.722 (0.614-0.849) <0.001|
| No                        | 0.814 (0.594-1.115) 0.201| 0.812 (0.593-1.113) 0.196|
| **Type of pulmonary TB**  |                          |                       |
| Known (BL)                | 1.287 (1.132-1.463) <0.001| 1.286 (1.131-1.463) <0.001|
| Unknown                   | 0.929 (0.806-1.071) 0.309| 0.929 (0.806-1.071) 0.309|
| **Contact history**       |                          |                       |
| Yes                       | 0.675 (0.605-0.753) <0.001| 0.668 (0.599-0.746) <0.001|

*HR: Hazard ratio
DISCUSSION

This study was designed to explore the treatment delay and total delay among TB patients and to explore relationships between various characteristics of the study participants and patients’ treatment delay and total delay in Mazandaran province in 2009-2015. In our study, the median treatment delay was found as 35 while total delay was 36 days. We have found that the median total delay was lower in men, patients in the ≤14 year-old age group, prisoner patients, rural patients, patients who have not received an HIV test, smear negative patients, those who are Iranian, and patients whose contact history was unknown. Treatment delay was the same as total delay, except for the variable of place of residence; the median treatment delay among urban patients was less than that among rural patients.

A systematic review that investigated delays in diagnosis and treatment of pulmonary tuberculosis in India revealed that the median treatment delay was 2.5 days (1.9–3.6) which was shorter than the treatment delay found in our study (17). Other studies have also found shorter median for treatment delay, such as those in Guinea-Bissau (12.1 weeks) (18), in Tanzania (28 days) (19), in Botswana (5 weeks) (20), in Ethiopia (2 days) (21), and in Nigeria (11 weeks) (22). In a study conducted in Nigeria, it was found that the median treatment delay was one week and the median total delay was 10 weeks, which were longer than the delays found in our study (23).

Another study (24) which investigated the diagnostic and treatment delays for tuberculosis in 7 countries within the eastern Mediterranean region revealed that the longest mean of treatment delay was in Iran, with 127 days; however, our study showed a lower delay of 68.29 days. In a study conducted in Markazi province, the results showed that the mean of total delay and treatment delay were129.9±171 and 2.1±5.2, respectively. In addition, there were no significant associations between gender and nationality with treatment delay (25). However, the mean of total delay and treatment delay were found to be 69.93 and 68.29 in our study, both of which are greater than the abovementioned study. On the other hand, there were no associations between gender and nationality with treatment delay in both studies. The differences between values found for delays could be due to variation in the selection of the study population, difference in treatment delay definition as they may differ in various countries. Our findings could be related to poorer transportation system in Mazandaran province.

In a study by Lorent et al., one of the risk factors for delay in the diagnosis and treatment of TB among 104 patients with a mean age of 35 years (range 17–84) was the patient’s HIV status as 62% was found to be HIV-positive;
no significant association was found between treatment delay, age, and gender (26). However, our results showed significant association between patients who received an HIV test and those who did not, and treatment delay and total delay.

This might be due to the difference in the number of patients, as there were 104 patients in the study by Lorent, N et al. while our study had 1694 patients. Additionally, the number of patients who were HIV-positive is significantly higher in that study (26 HIV-positive patients) as compared to our study. The possible reason for this difference might be that the patients in our study may not have had the inclination to take an HIV test; therefore, the HIV status of most of the patients in our study was unknown.

In a study by Charati and Kazemnegad, 89.2% of TB patients identified in Mazandaran province in 2008 were not evaluated for HIV. Only 25 TB cases were examined for HIV and 3 of those were HIV positive. In this study, the percentage of patients whose HIV status were unknown was 82.2%, but the number of patients who received the test were 301 (17.77%) cases which shows that HIV testing had increased since the above mentioned study (5).

Chiang, et al. (27) studied the patient- and health system-related delays in the diagnosis and treatment of tuberculosis in a population-based patient interview study. Results showed that being younger than 65 years was associated with longer treatment delay; based on the findings from many other studies, diagnosis and treatment delays were found to significantly increase with age (28-35).

In our study, there were significant associations between age and treatment delay, with the median treatment delay and total delay increasing with the age. It might be due to the feeble performance of the physicians in the diagnosis of TB among elderly people. This weakness in the diagnosis may be due to the possibility that physicians are not able to recognize and differentiate TB symptoms when there are underlying diseases. Information on better case detection should be included in trainings to familiarize the personnel and medical staff with the signs and symptoms of TB; equipping the laboratories appropriately will also enable them to diagnose TB cases better and efficiently (17).

In a study by Lienhardt et al., a total of 152 TB patients were interviewed. The median delay from the onset of symptoms to commencement of treatment was 8.6 weeks (range 5–17). Treatment delay was independent of gender, but was shorter in young TB patients. The median delay was longer in the rural areas than that in urban areas (28). In our study, it was found that total delay was less than the abovementioned study and women had longer treatment delay than men, which may be because many women depend on their husbands or male relatives to bring them in for treatment because of the difficulties with transportation (36).

The high number of TB patients found in the rural areas 687 (40.5%) indicate the availability of more efficient health care service and better economic status in the rural areas as compared to the cities and urban areas. Our result in this regard was in agreement with a study that was conducted by Yazdani-Chrati J et al. (37).

According to the results the high percent of patient’s contact history were unknown (30.7%) and had significant relationship with total and treatment delays. The hazard ratio for patients who their contact history’s status was unknown was less than patients who had not contact with TB patients. It can due to patients who their contact history were unknown were belonged to patients who had contact history category and didn’t evaluate and assess completely.

As our results showed the longest estimated median time for treatment delay and total delay were among patients who are not in prison versus patients who are in prison and were 38 and 41 days, respectively.

In addition, 2.1% of the 192 prisoners who received an HIV test were infected with HIV. This suggests that if all prisoners were to receive the HIV test, the number of diagnosed cases would increase. Moosazadeh et al. published a short report on the incidence of TB among the
prisoners in Mazandaran province, showing that 7 prisoners (0.3%) were infected with HIV, and overall 147 (6.1%) of the prisoners were TB patients (38).

CONCLUSION

The estimated median treatment delay and total delay were 35 and 36 days, respectively. We also found in our study that variables such as age, prison status, HIV testing, and patients who their contact history were unknown, had a significant relationship with the treatment delay and total delay (p-value<0.05).

Considering that the delay in TB treatment in our study was high and that TB is a contagious disease, it is recommended that diagnostic methods for TB should be emphasized in the training courses for medical students, continuing education courses for general physicians and specialists, and in post-graduate courses. To reduce the treatment delay, clinics need to be more involved and the referral mechanism must be strengthened. We also need to improve awareness of the symptoms of tuberculosis both in the general public and among health care professionals. There has not been any studies regarding the delays among pulmonary tuberculosis patients in Mazandaran province and this study reports the situation regarding the delays among pulmonary tuberculosis patients in Mazandaran province, and provides recommendations for improvements to help with the planning to reduce these delays, and hence reduce the period of treatment. One of the limitations of our study was that the registry data had recording errors. Additionally, it is possible that not all of the patients in this province had been registered. We also noted that the information on social and economic variables was not complete and these variables could have an effect on treatment delay and total delay.

Acknowledgement

Hereby the authors express their gratitude to the staff of the Center for Disease Control affiliated with the Health Deputy of Mazandaran University of Medical Sciences and Babol University of Medical Sciences for their sincere cooperation and financial support.

REFERENCES

1. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008;5(7):e152.
2. Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011;9:81.
3. Jiménez-Corona ME, Cruz-Hervert LP, García-García L, Ferreyra-Reyes L, Delgado-Sánchez G, Bobadilla-Del-Valle M, et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax 2013;68(3):214-20.
4. World Health Organization/Global Tuberculosis Report 2016/ Published on 12 Oct 2016/ Available at: http://reliefweb.int/report/world/global-tuberculosis-report-2016/Accessed December 19, 2016.
5. Charati JY, Kazemnegad A. Spatial distribution of tuberculosis in Mazandaran Province–Iran: Spatiotemporal modeling. Tanaffos 2010;9(3):15-21.
6. Yazdani Charati J, Kazemnejad A, Mosazadeh M. An epidemiological study on the reported cases of tuberculosis in Mazandaran (1999-2008) using spatial design. Journal of Mazandaran University of Medical Sciences 2010;19(74):9-16.
7. Ministry of Health and Medical Education, Center contagious diseases, Iran. Iranian centre for disease control and prevention, division of TB and leprosy elimination, Iran: Ministry of Health and Medical Education; 2011. Available at: http://tb-lep.behdasht.gov.ir/TB_Situation_in_Iran.aspx/ Accessed December 19, 2016 (In Persian).
8. Jochem K, Walley J. Determinants of the tuberculosis burden in populations. Tuberculosis–an interdisciplinary perspective. London: Imperial College. 1999:33-48.
9. Golub JE, Bur S, Cronin WA, Gange S, Baruch N, Comstock GW, Chaisson RE. Delayed tuberculosis diagnosis and tuberculosis transmission. Int J Tuberc Lung Dis 2006;10(1):24-30.

Tanaffos 2017; 16(1): 13-21
10. World Health Organization. Tuberculosis, Fact Sheet No. 104, 2007. Site accessed: www.who.int/mediacentre/factsheets/who104/en/index.html. 2016.

11. Xu B, Jiang QW, Xiu Y, Diwan VK. Diagnostic delays in access to tuberculosis care in counties with or without the National Tuberculosis Control Programme in rural China. *Int J Tuberc Lung Dis* 2005;9(7):784-90.

12. WHO T. Groups at Risk, WHO Report on the Tuberculosis Epidemic. Geneva: World Health Organization. 1996.

13. Lienhardt C, Rowley J, Manneh K, Lahai G, Needham D, Milligan P, McAdam KP. Factors affecting time delay to treatment in a tuberculosis control programme in a sub-Saharan African country: the experience of The Gambia. *Int J Tuberc Lung Dis* 2001;5(3):233-9.

14. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. *BMC Public Health* 2008;8:15.

15. Pablos-Méndez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. *JAMA* 1996;276(15):1223-8.

16. Kleinbaum DG, Klein M. Survival analysis: a self-learning text. Springer Science & Business Media; 2006.

17. Sreramareddy CT, Qin ZZ, Satyanarayana S, Subbaraman R, Pai M. Delays in diagnosis and treatment of pulmonary tuberculosis in India: a systematic review. *Int J Tuberc Lung Dis* 2014;18(3):255-66.

18. Virenfeldt J, Rudolf F, Camara C, Furtado A, Gomes V, Aaby P, et al. Treatment delay affects clinical severity of tuberculosis: a longitudinal cohort study. *BMJ Open* 2014;4(6):e004818.

19. Ngadaya ES, Mfinanga GS, Wandwalo ER, Morkve O. Delay in tuberculosis case detection in Pwani region, Tanzania. A cross sectional study. *BMC Health Serv Res* 2009;9:196.

20. Steen TW, Mazonde GN. Pulmonary tuberculosis in Kweneng District, Botswana: delays in diagnosis in 212 smear-positive patients. *Int J Tuberc Lung Dis* 1998;2(8):627-34.

21. Yimer S, Bjune G, Alene G. Diagnostic and treatment delay among pulmonary tuberculosis patients in Ethiopia: a cross sectional study. *BMC Infect Dis* 2005;5:112.

22. Ukwaja KN, Alobu I, Nweke CO, Onyenwe EC. Healthcare-seeking behavior, treatment delays and its determinants among pulmonary tuberculosis patients in rural Nigeria: a cross-sectional study. *BMC Health Serv Res* 2013;13:25.

23. Odusanya OO, Babafemi JO. Patterns of delays amongst pulmonary tuberculosis patients in Lagos, Nigeria. *BMC Public Health* 2004;4:18.

24. Bassili A, Seita A, Baghdadi S, ALAbsi A, Abdelai I, Agboatwalla M, et al. Diagnostic and treatment delay in tuberculosis in 7 countries of the Eastern Mediterranean Region. *Infectious Diseases in Clinical Practice* 2008;16(1):23-35.

25. Mohammadbeigi A, Bakhtiari M, Dalirian S, Mokhtari M, Jadidi R. Delay in diagnosis and treatment of pulmonary tuberculosis and its association with some social and personal characteristics in Markazi Province (2008-2014). *Koomesh* 2016;17(4).

26. Lorent N, Mugwaneza P, Mugabekazi J, Gasana M, Van Bastelaere S, Clerinx J, et al. Risk factors for delay in the diagnosis and treatment of tuberculosis at a referral hospital in Rwanda. *Int J Tuberc Lung Dis* 2008;12(4):392-6.

27. Chiang CY, Chang CT, Chang RE, Li CT, Huang RM. Patient and health system delays in the diagnosis and treatment of tuberculosis in Southern Taiwan. *Int J Tuberc Lung Dis* 2005;9(9):1006-12.

28. Lienhardt C, Rowley J, Manneh K, Lahai G, Needham D, Milligan P, et al. Factors affecting time delay to treatment in a tuberculosis control programme in a sub-Saharan African country: the experience of The Gambia. *Int J Tuberc Lung Dis* 2001;5(3):233-9.

29. Kiwuwa MS, Charles K, Harriet MK. Patient and health service delay in pulmonary tuberculosis patients attending a referral hospital: a cross-sectional study. *BMC Public Health* 2005;5:122.

30. Karim F, Islam MA, Chowdhury AM, Johansson E, Diwan VK. Gender differences in delays in diagnosis and treatment of tuberculosis. *Health Policy Plan* 2007;22(5):329-34.

31. Huong NT, Vree M, Duong BD, Khanh VT, Loan VT, Co NV, et al. Delays in the diagnosis and treatment of tuberculosis...
patients in Vietnam: a cross-sectional study. **BMC Public Health** 2007;7:110.

32. Pehme L, Rahu K, Rahu M, Altraja A. Factors related to health system delays in the diagnosis of pulmonary tuberculosis in Estonia. **Int J Tuberc Lung Dis** 2007;11(3):275-81.

33. Pirkis JE, Speed BR, Yung AP, Dunt DR, Maclntyre CR, Plant AJ. Time to initiation of anti-tuberculosis treatment. **Tuber Lung Dis** 1996;77(5):401-6.

34. Gagliotti C, Resi D, Moro ML. Delay in the treatment of pulmonary TB in a changing demographic scenario. **Int J Tuberc Lung Dis** 2006;10(3):305-9.

35. Lin HP, Deng CY, Chou P. Diagnosis and treatment delay among pulmonary tuberculosis patients identified using the Taiwan reporting enquiry system, 2002-2006. **BMC Public Health** 2009;9:55.

36. Khazaei HA, Rezaei N, Bagheri GR, Dankoub MA, Shahryari K, Tahai A, et al. Epidemiology of tuberculosis in the Southeastern Iran. **Eur J Epidemiol** 2005;20(10):879-83.

37. Yazdani-Charati J, Mrdanshah F, Etemad-Nejad S, Rezaei MS, Ghadami M, Ahmadi-Baseri E. Application of empirical Bayes smoothed incidence rates of tuberculosis during the year 2005-2011 to prepare geographical map of tuberculosis incidence. **Journal of Mazandaran University of Medical Sciences** 2014;23(110):45-56.

38. Moosazadeh M, Amiresmaili MR, Parsaei MR, Ahmadi M, Jalahi H. Prevalence of tuberculosis among the prisoners of Mazandaran. **Journal of Rafsanjan University of Medical Sciences** 2011;10(4):309-16.